Immune evasion contributes to cancer growth and progression. Cancer cells have the ability
to activate different immune checkpoint pathways that harbor immunosuppressive functions …

Tumor drug resistance emerges from the interaction of two critical factors: tumor cellular
heterogeneity and the immunosuppressive nature of the tumor microenvironment (TME) …

Obesity is a leading risk factor for progression and metastasis of many cancers,, yet can in
some cases enhance survival,–and responses to immune checkpoint blockade therapies …

Programmed cell death 1 receptor (PD-1) and its ligands constitute an inhibitory pathway to
mediate the mechanism of immune tolerance and provide immune homeostasis …

Reactive oxygen species (ROS) are a group of short-lived highly reactive molecules formed
intracellularly from molecular oxygen. ROS can alter biochemical, transcriptional, and …

Immune responses must be tightly regulated to ensure both optimal protective immunity and
tolerance. Costimulatory pathways within the B7: CD28 family provide essential signals for …

During the past decade, there has been a revolution in cancer therapeutics by the
emergence of antibody-based immunotherapies that modulate immune responses against …

The protein phosphatase SHP2/PTPN11 has been reported to be a key modulator of
proliferative pathways in a wide range of malignancies. Intriguingly, SHP2 has also been …

Аbstract With increasing incidence and geography, cancer is one of the leading causes of
death, reduced quality of life and disability worldwide. Principal progress in the development …

Mutant selective drugs targeting the inactive, GDP-bound form of KRASG12C have been
approved for use in lung cancer, but resistance develops rapidly. Here we use an …